Insmed CEO on what's next for company after FDA greenlights lung disease drug
- Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.
- 08/13/2025
|
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
- The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
- 08/12/2025
|
US FDA approves Insmed's lung disease drug
- The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.
- 08/12/2025
|
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
- — Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed to Host Investor Conference Call Today at 12:00 PM ET — BRIDGEWATER, N.J. , Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved first-in-class BRINSUPRI™ (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
- 08/12/2025
|
Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock
- Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
- 08/11/2025
|
Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Bryan Dunn - Vice President of Investor Relations Martina Flammer - Chief Medical Officer Roger Adsett - Chief Operating Officer Sara M. Bonstein - Chief Financial Officer William H.
- 08/07/2025
|
Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/07/2025
|
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.7 per share versus the Zacks Consensus Estimate of a loss of $1.3. This compares to a loss of $1.94 per share a year ago.
- 08/07/2025
|
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
- —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —TPIP Program Advancing with Phase 3 Studies Planned to Begin for PH-ILD in the Second Half of 2025 and for PAH in Early 2026— —Topline Data Anticipated for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP by the End of 2025— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— BRIDGEWATER, N.J. , Aug. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2025 and provided a business update.
- 08/07/2025
|
Insmed (INSM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Beyond analysts' top-and-bottom-line estimates for Insmed (INSM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
- 08/05/2025
|
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
- Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/31/2025
|
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
- BRIDGEWATER, N.J. , July 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2025 financial results on Thursday, August 7, 2025.
- 07/24/2025
|
It is time for a move higher in biotech, says Mizuho's Jared Holz
- Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
- 07/07/2025
|
Russell Rebalance: 3 Stocks Ready to Move Higher
- Investors pay close attention to the quarterly rebalancing of the S&P 500 index for good reason. First, the stocks in the S&P 500 make up approximately 80% of the total U.S. equity market.
- 06/20/2025
|
Is Insmed Stock Overvalued After The 45% Jump?
- Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?
- 06/16/2025
|
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
- BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share.
- 06/11/2025
|
Insmed Announces Proposed $650 Million Public Offering of Common Stock
- BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an underwritten public offering.
- 06/11/2025
|
United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock
- United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Insmed's treprostinil based product seemingly edged United's Tyvaso on key measures such as pulmonary vascular resistance and 6-minute walk test. United's PAH products account for >90% of its revenues and it already faces a threat from Liquidia's Yutrepia.
- 06/11/2025
|
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
- Insmed Incorporated INSM on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension.
- 06/11/2025
|
Insmed Stock Jumps 29% on Encouraging PAH Study Results
- INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
- 06/11/2025
|
Insmed CEO Will Lewis on stock surge after positive trial results
- Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.
- 06/10/2025
|
Insmed: Company Presses On With Further POC PAH Treatment Data
- Insmed achieved positive phase 2b results for TPIP in PAH, meeting all endpoints and paving the way for phase 3 trials in 2025-2026. The global pulmonary arterial hypertension market is expected to reach $12.2 billion by 2032. Brensocatib's NDA for bronchiectasis is under Priority Review, with a PDUFA date of August 12, 2025, targeting an untapped market.
- 06/10/2025
|
Liquidia price target lowered by $2 at BofA, here's why
- Liquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun
- 06/10/2025
|
Insmed shares surge on positive trial results for pulmonary arterial hypertension therapy
- Insmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The randomized, double-blind, placebo-controlled study met its primary endpoint as well as all secondary efficacy endpoints.
- 06/10/2025
|
Insmed's blood pressure drug meets main goal in mid-stage trial
- Insmed said on Tuesday that its experimental blood pressure drug met the main goals in a mid-stage study.
- 06/10/2025
|
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
- –The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p
- 06/10/2025
|
Mizuho's Jared Holz details potential biotech, pharma acquisitions
- Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.
- 06/04/2025
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , June 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 150 new employees.
- 06/04/2025
|
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
- BRIDGEWATER, N.J. , May 28, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2025 Goldman Sachs Annual Global Healthcare Conference in Miami on Wednesday, June 11, 2025, at 9:20 a.m.
- 05/28/2025
|
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
- — Insmed Presented 11 Abstracts at ATS 2025 from Across Its Respiratory Portfolio, Including Data on ARIKAYCE® , TPIP and Health Economics and Outcomes Research — BRIDGEWATER, N.J. , May 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, presented 11 new abstracts at the American Thoracic Society (ATS) 2025 International Conference, which took place May 18-21 in San Francisco, including three prespecified subgroup analyses from the Phase 3 ASPEN trial of brensocatib in non-cystic fibrosis bronchiectasis (NCFBE), signaling the consistency of efficacy and safety outcomes across diverse clinical profiles.
- 05/21/2025
|
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects
- Examine the evolution of Insmed's (INSM) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
- 05/13/2025
|
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
- INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
- 05/09/2025
|
Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Andrea Newkirk - Goldman Sachs Jason Zemansky - Bank of America Nick Lenard - JPMorgan Joe Schwartz - Leerink Partners Ritu Baral - TD Cowen Jennifer Kim - Cantor Fitzgerald Liisa Bayko - Evercore Graig Suvannavejh - Mizuho Securities Leonid Timashev - RBC Nicole Germino - Truist Securities Maxwell Skor - Morgan Stanley Trung Huynh - UBS Emma Gutstein - Wolfe Research Operator Thank you for standing-by. My name is Amy, and I will be your conference operator for today.
- 05/08/2025
|
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago.
- 05/08/2025
|
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
- —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— BRIDGEWATER, N.J. , May 8, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a business update.
- 05/08/2025
|
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
- Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2025
|
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
- Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
- 04/29/2025
|
Insmed To Present at the BofA Securities 2025 Health Care Conference
- BRIDGEWATER, N.J. , April 29, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m.
- 04/29/2025
|
Insmed: Poised For Transformation Beyond ARIKAYCE
- Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 results for non-cystic fibrosis bronchiectasis, with a potential FDA approval by August 2025, highlighting a significant market opportunity. Insmed's diversified pipeline, including TPIP and INS1201, reduces reliance on a single product and enhances long-term growth prospects.
- 04/25/2025
|
Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
- BRIDGEWATER, N.J. , April 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes Due 2028 (the "Notes") (CUSIP No.
- 04/24/2025
|
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
- —Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Brensocatib 25 mg is the First Investigational Therapy for Bronchiectasis to Show a Statistically Significant Reduction in the Rate of Lung Function Decline— —Brensocatib is Currently Under Priority Review with the U.S. Food and Drug Administration— BRIDGEWATER, N.J. , April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the New England Journal of Medicine (NEJM).
- 04/23/2025
|
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
- BRIDGEWATER, N.J. , April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2025.
- 04/23/2025
|
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
- —New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial— — Data on Health Status Improvements Over Time Following Culture Conversion in Patients with Mycobacterium Avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J. , March 25, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present 11 abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco.
- 03/25/2025
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees.
- 03/10/2025
|
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
- RBC Capital Markets has initiated coverage on Insmed Inc INSM, citing brensocatib's launch momentum.
- 02/25/2025
|
International Markets and Insmed (INSM): A Deep Dive for Investors
- Examine Insmed's (INSM) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
- 02/24/2025
|
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
- —FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis.
- 02/24/2025
|
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
- INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
- 02/21/2025
|
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
- Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
- 02/20/2025
|
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/20/2025
|
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to loss of $1.28 per share a year ago.
- 02/20/2025
|
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
- —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH, Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP, and Phase 3 ENCORE Study of ARIKAYCE Remain on Track for Topline Data in Mid-2025, End of 2025, and First Quarter of 2026, Respectively— —Company Ends 2024 with Approximately $1.4 Billion of Cash, Cash Equivalents, and Marketable Securities— BRIDGEWATER, N.J. , Feb. 20, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.
- 02/20/2025
|
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
- Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
- 02/17/2025
|
Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
- 02/17/2025
|
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/13/2025
|
Insmed To Present at March 2025 Investor Conferences
- BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 45th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 3, 2025, at 9:10 a.m.
- 02/11/2025
|
Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025
- BRIDGEWATER, N.J. , Feb. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2024 financial results on Thursday, February 20, 2025.
- 02/10/2025
|
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
- Insmed's Arikayce, a treatment for MAC and NTM lung diseases, generated $93.4m in Q3 2023, with full-year revenue guidance of $340m-$360m. Brensocatib, Insmed's lead pipeline candidate for non-CF bronchiectasis, received FDA Priority Review with a target action date of August 12, 2025. This is a potential multi-billion dollar selling asset. Brensocatib's market potential is significant, with Wall Street analysts projecting peak annual revenues exceeding $5bn, bolstering Insmed's market cap of $14.45bn.
- 02/07/2025
|
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
- The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
- 02/07/2025
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees.
- 02/07/2025
|
FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
- —Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J. , Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis.
- 02/06/2025
|
Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference
- --ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Compared to 2024-- --NDA for Brensocatib in Bronchiectasis Submitted to FDA in December 2024, Narrowing the Timing for Expected U.S. Launch to the Third Quarter of 2025, Pending Approval Under Priority Review-- --Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025-- --Phase 3 ENCORE Trial for ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled; Topline Data Anticipated in First Quarter of 2026-- --IND Cleared for Insmed's First Gene Therapy (INS1201) for Patients with DMD; First Patient Dosing Anticipated in the First Half of 2025-- BRIDGEWATER, N.J. , Jan. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company's commercial and clinical programs and its outlook for 2025.
- 01/10/2025
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 19 new employees.
- 01/03/2025
|
Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
- BRIDGEWATER, N.J. , Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43rd Annual J.P.
- 01/02/2025
|
5 Biotech Breakthrough Stocks to Watch in 2025
- After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
- 12/23/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Dec. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 30 new employees.
- 12/06/2024
|
Insmed To Present at December 2024 Investor Conferences
- BRIDGEWATER, N.J. , Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 11:15 a.m.
- 12/02/2024
|
Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
- Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA filing for bronchiectasis is expected in Q4 2024 and could lead to a U.S. launch by mid-2025. Top-line results from the phase 2b study, using TPIP for the treatment of patients with PAH, expected in the 2nd half of 2025.
- 11/20/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees.
- 11/07/2024
|
Insmed To Present at November 2024 Investor Conferences
- BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference in Boston on Monday, November 11, 2024, at 1:00 p.m.
- 11/06/2024
|
Insmed (INSM) Reliance on International Sales: What Investors Need to Know
- Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
- 11/04/2024
|
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
- INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.
- 11/01/2024
|
Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Joe Schwartz – Leerink Partners Jessica Fye – JPMorgan Nicole Germino – Truist Securities Jason Zemansky – Bank of America Jennifer Kim – Cantor Jeff Hung – Morgan Stanley Leon Wang – Barclays Steve Willey – Stifel Graig Suvannavejh – Mizuho Operator Thank you for standing by. My name is Jeannie, and I will be your conference operator today.
- 10/31/2024
|
Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 10/31/2024
|
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago.
- 10/31/2024
|
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
- —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025— —Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awareness and Supporting the Growth of ARIKAYCE Prior to the Anticipated Launch of Brensocatib— —Ends the Third Quarter with ~$1.5 Billion in Cash, Cash Equivalents, and Marketable Securities— —Renegotiates Term Loan with Pharmakon Resulting in a Lower Cost of Capital and an Additional $150 Million in Proceeds to be Received in the Fourth Quarter— —Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Oct. 31, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
- 10/31/2024
|
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
- 10/30/2024
|
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
- —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J. , Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey.
- 10/24/2024
|
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
- Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J. , Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its third annual Global Day of Good, with more than 1,000 employees volunteering simultaneously in their respective communities around the world.
- 10/23/2024
|
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/17/2024
|
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
- BRIDGEWATER, N.J. , Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024.
- 10/17/2024
|
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
- —Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J. , Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
- 10/08/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Oct. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 52 new employees.
- 10/04/2024
|
These 12 Stocks are Ripe for a Short Squeeze
- Subscribers to Chart of the Week received this commentary on Sunday, September 8.
- 09/10/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 60 new employees.
- 09/06/2024
|
Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach
- Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025, pending regulatory approval in Q4 2024. Insmed's R&D expenses were $146.7 million in Q2 2024, down from the previous year due to prior non-cash acquisition costs.
- 08/28/2024
|
Insmed Stock Surges 168% in the Past Six Months: Here's Why
- Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
- 08/27/2024
|
Meta Stock Leads 5 Names Near Buy Points As Market Bounces
- Meta leads five stocks near buy points as the market rallied Friday on Fed Chair Jerome Powell's speech.
- 08/24/2024
|
Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Bryan Dunn – Head-Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Jessica Fye – JPMorgan Ritu Baral – TD Cowen Joseph Schwartz – Leerink Partners Cameron Bozdog – Bank of America Jennifer Kim – Cantor Fitzgerald Leon Wang – Barclays Vamil Divan – Guggenheim Securities Liisa Bayko – Evercore ISI Graig Suvannavejh – Mizuho Nicole Germino – Truist Securities Andrea Tan – Goldman Sachs Operator Thank you for standing by. My name is John, and I will be your conference operator for today.
- 08/09/2024
|
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
- Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
- 08/09/2024
|
Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/08/2024
|
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.94 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.78 per share a year ago.
- 08/08/2024
|
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
- —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— —Primary Endpoint for ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Infection Agreed Upon with U.S. FDA— —Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Aug. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.
- 08/08/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Aug. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 97 new employees.
- 08/02/2024
|
Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024
- BRIDGEWATER, N.J. , July 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2024 financial results on Thursday, August 8, 2024.
- 07/29/2024
|
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , July 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees.
- 07/05/2024
|
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
- —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score— BRIDGEWATER, N.J. , July 3, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented tomorrow, July 4, 2024, at the 7th World Bronchiectasis Conference (WBC) in Dundee, Scotland.
- 07/03/2024
|
Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
- BRIDGEWATER, N.J. , June 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its outstanding 1.75% Convertible Senior Notes Due 2025 (the "Notes") (CUSIP No.
- 06/27/2024
|
Top 4 Health Care Stocks That May Keep You Up At Night This Month
- As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
- 06/11/2024
|
3 Biotech Stocks to Monitor Right Now
- Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
- 06/10/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , June 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees.
- 06/07/2024
|
Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- BRIDGEWATER, N.J. , June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024, at 10:00 a.m.
- 06/05/2024
|
Insmed (INSM) CEO on the Company's Current Product Pipeline
- Insmed (INSM) announced positive topline results from an Aspen Phase 3 study of Brensocatib. Insmed is a biopharmaceutical company that develops therapies for patients with serious and rare diseases.
- 06/04/2024
|
Insmed to Host Commercial Webinar on June 4, 2024
- BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m.
- 05/30/2024
|
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
- BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share.
- 05/30/2024
|
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
- Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
- 05/29/2024
|
Insmed CEO on lung disease treatment and path forward
- Will Lewis, Insmed CEO, joins 'Fast Money' to talk its latest lung disease treatment, growth opportunity and more.
- 05/28/2024
|
Insmed Announces Proposed $500 Million Public Offering of Common Stock
- BRIDGEWATER, N.J. , May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.
- 05/28/2024
|
Insmed Stock More Than Doubled in Value Tuesday—Here's Why
- Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study of its experimental drug to reduce symptoms in patients with a rare lung disease.
- 05/28/2024
|
Chart of the Day: Insmed
- Michelle Ross, StemPoint Capital Chief Investment Officer & Managing Parter, joins us with the latest on the stock and a few more biotech names she's watching.
- 05/28/2024
|
Insmed shares skyrocket on positive trial results for lung drug
- Insmed Incorporated (NASDAQ:INSM) shares more than doubled after the company released positive results from its late-stage study of its experimental therapy brensocatib for a lung condition. The company said patients in the study with non-cystic fibrosis bronchiectasis who were dosed with brensocatib saw statistically significant reductions in the annualized rate of pulmonary exacerbations compared to placebo.
- 05/28/2024
|
Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
- Brensocatib, Insmed's DPP1 inhibitor, showed significant efficacy in the Phase 3 ASPEN study for treating NCFB. Insmed's financial position includes high R&D costs with a solid short-term liquidity ratio but substantial long-term debt. Peak revenue estimates for brensocatib range from $1-5 billion, with a reasonable midpoint of $3 billion expected.
- 05/28/2024
|
Insmed Catapults 128% After Proving Its Theory In A 'Large, Untapped' Lung Disease Market
- Insmed stock catapulted Tuesday after the biotech company experimental lung disease treatment succeeded in a final-phase study.
- 05/28/2024
|
Why Is Insmed (INSM) Stock Up 134% Today?
- Insmed (NASDAQ: INSM ) stock is rising higher on Tuesday after the company announced positive results from a Phase 3 clinical trial of brensocatib in patients with non-cystic fibrosis bronchiectasis. This saw brensocatib reach its primary endpoint of statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) versus placebo.
- 05/28/2024
|
Insmed's stock rockets toward a 2-decade high after positive drug-trial data
- Shares of Insmed Inc. skyrocketed Tuesday, after the biopharmaceutical company said it plans to file a New Drug Application for its treatment of non-cystic fibrosis bronchiectasis following positive Phase 3 trial results.
- 05/28/2024
|
Insmed's lung disease drug succeeds in late-stage study
- Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study, prompting its shares to double in premarket trading on Tuesday.
- 05/28/2024
|
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
- —Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Treatment with Brensocatib Also Achieves Statistical Significance on Multiple Secondary Endpoints for Both Dosage Strengths Versus Placebo— —Brensocatib Well-Tolerated at Both Dosage Strengths— —Results from ASPEN Validate DPP1 Inhibition as New Mechanism of Action with Potential to Address Range of Neutrophil-Mediated Diseases— —Insmed Plans to Advance Quickly Toward U.S. Regulatory Filing, with Anticipated U.S. Launch in Mid-2025, Pending Approval— —Insmed to Host Investor Call at 8:00 am ET on Tuesday, May 28, 2024— BRIDGEWATER, N.J. , May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
- 05/28/2024
|
Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
- —Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET— BRIDGEWATER, N.J. , May 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
- 05/27/2024
|
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
- —Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument— — QOL-B Respiratory Domain Scores for ARIKAYCE Patients Showed Improvement Through Month 6 and Continued to Improve Through Month 7 (1 Month Off Treatment), While Improvements in the Comparator Arm Plateaued After Month 3 and Worsened After Month 6 — —Microbiologic Data Presented Showed Patients in the ARIKAYCE-treated Arm Had Numerically Greater Rates of Culture Conversion By Month 6, and Nominally Statistically Significantly Higher Rates By Month 7, With Earlier Time to First Culture Conversion vs.
- 05/20/2024
|
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
- Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
- 05/10/2024
|
Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript
- Insmed, Inc. (NASDAQ:INSM ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Bryan Dunn - Executive Director, Investor Relations William Lewis - Chairman, President & CEO Eugene Sullivan - Chief Product Strategy Officer & Chief Scientific Officer Sara Bonstein - CFO Conference Call Participants Andrea Tan - Goldman Sachs & Co. Jessica Fye - JPMorgan Securities Leon Wang - Barclays Capital Joseph Schwartz - Leerink Partners Nicole Germino - Truist Securities Jason Zemansky - Bank of America Merrill Lynch Ritu Baral - Cowen & Co. Jeff Hung - Morgan Stanley Liisa Bayko - Evercore ISI Jennifer Kim - Cantor Fitzgerald Stephen Willey - Stifel Operator Thank you for standing by. My name is Dee, and I will be your conference operator today.
- 05/09/2024
|
Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 05/09/2024
|
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.17 per share a year ago.
- 05/09/2024
|
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
- — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Data from the Phase 2 PH-ILD Study of TPIP with 79.3% of Patients Reaching the Maximum Dose of 640 µg by Week 5, with an Unexpectedly Positive and Robust Signal on the Exploratory Endpoint of Clinical Worsening— —Encouraging Blinded Data from First 40 Patients in Phase 2 PAH Study of TPIP, with Combined Active Treatment and Placebo Arms Showing Mean PVR Reduction of 19.9% and 6-Minute Walk Distance Improvement of 43 Meters— —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Patients with Bronchiectasis Remains on Track to Read Out in the Latter Part of Second-Quarter 2024— —Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , May 9, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
- 05/09/2024
|
Should You Buy Insmed (INSM) Ahead of Earnings?
- Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/08/2024
|
Insmed To Present at the BofA Securities Health Care Conference 2024
- BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the BofA Securities Health Care Conference 2024 in Las Vegas, NV, on Tuesday, May 14, 2024 at 2:20 p.m.
- 05/07/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , May 3, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 63 new employees.
- 05/03/2024
|
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/02/2024
|
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
- BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.
- 04/25/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , April 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees.
- 04/05/2024
|
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
- —Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to be Presented from ARISE Examining Change in Patient-Reported Respiratory Symptoms— BRIDGEWATER, N.J. , March 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego.
- 03/27/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , March 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees.
- 03/05/2024
|
Insmed To Present at Three March Conferences
- BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 2:50 p.m.
- 02/29/2024
|
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
- Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
- 02/22/2024
|
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.
- 02/22/2024
|
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
- —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second-Quarter 2024 Ahead of the ASPEN Readout— —Company Ends 2023 With $780 Million of Cash, Cash Equivalents, and Marketable Securities, Providing Runway Beyond the Expected ASPEN Readout— — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $83.7 Million for Fourth-Quarter and $305.2 Million for Full-Year 2023, Reflecting 24% Annual Growth and Exceeding the Upper End of Full-Year 2023 Guidance Range— —Company Reiterates Sales Guidance for 2024 Global ARIKAYCE Revenues in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Feb. 22, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
- 02/22/2024
|
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/15/2024
|
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
- BRIDGEWATER, N.J. , Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.
- 02/08/2024
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J. , Feb. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees.
- 02/02/2024
|
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 per share a year ago.
- 10/26/2023
|
Why Shares of Insmed Are Soaring This Week
- Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter.
- 09/08/2023
|
Insmed (INSM) Up on Positive Data From MAC Lung Disease Study
- Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.
- 09/06/2023
|
Insmed stock climbs on positive study results; hits 52-week high
- Insmed Incorporated (NASDAQ:INSM) shares jumped 18% to $26.62 after the biopharmaceutical company revealed that nearly 44% of patients with nontuberculous mycobacterial (NTM) lung infection in its Phase 3 ARISE study saw an improvement in respiratory symptoms after receiving its Arikayce antibiotic treatment compared with about 33% who received a placebo. Insmed also noted that more Arikayce-treated patients tested negative for the bacteria after seven months of treatment than did the placebo recipients.
- 09/05/2023
|
Why Insmed Stock Is Soaring Today
- Insmed reported positive top-line results from a late-stage study of its antibiotic drug Arikayce. The data could improve the likelihood of success in another late-stage study of Arikayce.
- 09/05/2023
|
Insmed Incorporated (INSM) Q2 2023 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Bryan Dunn - Head, IR William Lewis - Chair & CEO Sara Bonstein - CFO Martina Flammer - Chief Medical Officer Conference Call Participants Judah Frommer - Credit Suisse Vamil Divan - Guggenheim Jennifer Kim - Cantor Fitzgerald Leon Wang - Barclays Jason Zemansky - Bank of America Stephen Willey - Stifel Liisa Bayko - Evercore Andrea Tan - Goldman Sachs Joseph Schwartz - Leerink Partners Operator Thank you for standing by. My name is Enrique, and I'll be your conference operator today.
- 08/06/2023
|
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
- Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will delve into the details of this transaction, provide an overview of both the guru and the traded company, and analyze the potential implications of this move for value investors.
- 07/28/2023
|
Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
- BRIDGEWATER, N.J. , June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Wednesday, June 14, 2023 at 1:20 p.m.
- 06/07/2023
|
Insmed Incorporated (INSM) Q1 2023 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bryan Dunn - Head of Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Nick Lenard - JPMorgan Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Jennifer Kim - Cantor Fitzgerald Leon Wang - Barclays Stephen Willey - Stifel Jason Zemansky - Bank of America Liisa Bayko - Evercore Michael Riad - Morgan Stanley Operator Good morning, and welcome to the Insmed First Quarter 2023 Financial Results. My name is Nandaja, and I will be your operator today.
- 05/06/2023
|
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
- Insmed (INSM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $0.80 per share a year ago.
- 05/04/2023
|
Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
- —Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease (COPD) to Be Shared in Oral Presentation— —Researchers to Present Subgroup Analysis from Phase 2 WILLOW Study Evaluating Brensocatib Treatment Outcomes by Disease Severity in Patients with Bronchiectasis— BRIDGEWATER, N.J. , March 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that eight presentations across three of its pillars—ARIKAYCE ® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be shared at the American Thoracic Society (ATS) 2023 International Conference, taking place May 19-24, 2023, in Washington, D.C.
- 03/24/2023
|
Insmed Incorporated (INSM) Q4 2022 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chair and CEO Sara Bonstein - CFO Conference Call Participants Jason Zemansky - Bank of America Jeff Hung - Morgan Stanley Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Joseph Schwartz - SVB Securities Stephen Willey - Stifel Leon Wang - Barclays Graig Suvannavejh - Mizuho Securities Jennifer Kim - Cantor Fitzgerald Operator Hello everyone and welcome the Insmed Fourth Quarter and Full Year 2022 Financial Results. My name is Nadia and I'll be coordinating the call today.
- 02/23/2023
|
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2023
|
Wall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade
- The mean of analysts' price targets for Insmed (INSM) points to a 98.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 01/24/2023
|
Insmed To Present at the Nasdaq 47th Investor Conference
- BRIDGEWATER, N.J. , Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47th Investor Conference in London on Wednesday, December 7 at 8:30 a.m.
- 11/30/2022
|
Insmed Incorporated (INSM) Q3 2022 Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET Company Participants Will Lewis - Chair & CEO Sara Bonstein - CFO Eleanor Barisser - IR Conference Call Participants Jeff Hung - Morgan Stanley Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Joseph Schwartz - SVB Securities Liisa Bayko - Evercore ISI Jennifer Kim - Cantor Fitzgerald Operator Good morning, and afternoon, and evening. My name is Darius, and I will be your conference operator today.
- 10/27/2022
|
Why Insmed's Shares Fell 14.7% on Wednesday
- The biotech company is raising money to help it launch another drug, but it's diluting current shareholders in the process.
- 10/19/2022
|
Insmed (INSM) Upgraded to Buy: What Does It Mean for the Stock?
- Insmed (INSM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/04/2022
|
Insmed Incorporated (INSM) CEO Will Lewis on Q2 2022 Results - Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Eleanor Barisser - Investor Relations Will Lewis - Chair & Chief Executive Officer Sara Bonstein - Chief Financial Officer Conference Call Participants Jeff Hung - Morgan Stanley Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Joori Park - SVB Securities Stephen Willey - Stifel Jennifer Kim - Cantor Fitzgerald Operator Good morning. My name is Dennis, and I will be your conference operator today.
- 08/05/2022
|
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Insmed Inc. (INSM) CEO Will Lewis on Q1 2022 Results - Earnings Call Transcript
- Insmed Inc. (NASDAQ:INSM ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chairman, CEO Sara Bonstein - CFO Conference Call Participants Andrea Tan - Goldman Sachs Anita Dushyanth - Berenberg Jeff Hung - Morgan Stanley Jennifer Kim - Cantor Fitzgerald Jessica Fye - JPMorgan Joseph Schwartz - SVB Securities Judah Frommer - Credit Suisse Ritu Baral - Cowen Stephen Willey - Stifel Operator Hello, everyone, and welcome to the Insmed First Quarter 2022 Financial Results Call. My name is Daisy, and I'll be coordinating today's call.
- 05/07/2022
|
Insmed Incorporated's (INSM) CEO Will Lewis on Q4 2021 Results - Earnings Call Transcript
- Insmed Incorporated's (INSM) CEO Will Lewis on Q4 2021 Results - Earnings Call Transcript
- 02/17/2022
|
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -6.74% and 10.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/17/2022
|
Eleison Pharmaceuticals: Betting On Late-Stage Candidates For Orphan Diseases
- Eleison Pharmaceuticals acquires, develops and commercializes late-stage therapies for orphan diseases with unmet needs. The Company's three pipeline candidates have received the Orphan Drug Designation by the FDA, and two of them also from the EMA.
- 01/28/2022
|
Insmed Incorporated's (INSM) CEO Will Lewis on Q3 2021 Results - Earnings Call Transcript
- Insmed Incorporated's (INSM) CEO Will Lewis on Q3 2021 Results - Earnings Call Transcript
- 10/28/2021
|
INSM Stock: $60 Price Target From Cantor Fitzgerald
- The shares of Insmed Incorporated (NASDAQ: INSM) have received a $60 price target from Cantor Fitzgerald. These are the details.
- 10/11/2021
|
Insmed Inc. (INSM) CEO Will Lewis on Q2 2021 Results - Earnings Call Transcript
- Insmed Inc. (INSM) CEO Will Lewis on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
Insmed (INSM) Sees Hammer Chart Pattern: Time to Buy?
- Insmed (INSM) has been struggling lately, but the selling pressure may be coming to an end soon.
- 08/06/2021
|
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -10.59% and 4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
- BRIDGEWATER, N.J., Aug. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
- 08/05/2021
|
Here's Why Insmed (INSM) is Poised for a Turnaround After Losing 19.5% in 4 Weeks
- Insmed (INSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 07/27/2021
|
Insmed To Present at Two June Conferences
- BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor events: The Jefferies Virtual Healthcare Conference on June 1, 2021 at 9:00 a.m.
- 05/25/2021
|
Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference
- BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the virtual American Thoracic Society (ATS) 2021 International Conference.
- 05/19/2021
|
Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes
- BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering") of 11,500,000 shares of its common stock (the "Shares"), including 1,500,000 Shares issued pursuant to the exercise in full of the underwriters' option to purchase additional Shares, at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and the previously announced registered underwritten public offering (the "Notes Offering") of $575 million aggregate principal amount of its 0.75% convertible senior notes due 2028 (the "Notes"), including $75 million aggregate principal amount of Notes purchased pursuant to the exercise in full of the underwriters' option to purchase additional Notes, solely to cover over-allotments.
- 05/13/2021
|
Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
- BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the "Shares") at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and a registered underwritten public offering of $500 million aggregate principal amount of its 0.75% convertible senior notes due 2028 (the "Notes").
- 05/11/2021
|
INSM Stock: Over 15% Decrease Intraday Explanation
- The stock price of Insmed Incorporated (NASDAQ: INSM) decreased by over 15% during intraday trading this morning. This is why it happened.
- 05/10/2021
|
Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
- BRIDGEWATER, N.J., May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "Shares") and $500 million aggregate principal amount of its convertible senior notes due 2028 (the "Notes") in separate concurrent underwritten public offerings, a portion of which will be used to repurchase Insmed's existing outstanding convertible senior notes due 2025.
- 05/10/2021
|
Insmed Incorporated (INSM) CEO Will Lewis on Q1 2021 Results - Earnings Call Transcript
- Insmed Incorporated (INSM) CEO Will Lewis on Q1 2021 Results - Earnings Call Transcript
- 05/08/2021
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- BRIDGEWATER, N.J., May 7, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to nine new employees.
- 05/07/2021
|
Insmed Reports First Quarter 2021 Financial Results and Provides Business Update
- BRIDGEWATER, N.J., May 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.
- 05/06/2021
|
ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR
- BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) who did not sufficiently respond to prior treatment with a multidrug regimen (MDR).
- 03/23/2021
|
Insmed Incorporated (INSM) CEO Will Lewis on Q4 2020 Results - Earnings Call Transcript
- Insmed Incorporated (INSM) CEO Will Lewis on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Insmed's Inhaled Treprostinil Palmitil Is Safe; Healthy Volunteers Study Show
- Insmed Incorporated (NASDAQ: INSM) has announced topline results from the Phase 1 study evaluating treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. The company plans to present complete data from this study at an upcoming medical meeting.
- 02/19/2021
|
Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)
- BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation...
- 02/19/2021
|
Top 10 Healthcare Stocks for the Future
- In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future .
- 11/29/2020
|
Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
- BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines...
- 11/13/2020
|
Insmed Incorporated (INSM) CEO Will Lewis on Q3 2020 Results - Earnings Call Transcript
- Insmed Incorporated (INSM) CEO Will Lewis on Q3 2020 Results - Earnings Call Transcript
- 10/29/2020
|
Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update
- BRIDGEWATER, N.J., Oct. 29, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2020, and...
- 10/29/2020
|
European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options
- BRIDGEWATER, N.J., Oct. 28, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Commission (EC) has granted marketing authorization for...
- 10/28/2020
|
Nuveen Asset Management LLC Acquires 22,894 Shares of Insmed Incorporated (NASDAQ:INSM)
- Nuveen Asset Management LLC boosted its holdings in Insmed Incorporated (NASDAQ:INSM) by 4.1% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 575,328 shares of the biopharmaceutical company’s stock after acquiring an additional 22,894 shares during the quarter. Nuveen Asset Management LLC owned 0.57% […]
- 09/29/2020
|
OSI Systems Receives $4 Million Order to Provide Optical Sensors
- OSI Systems, Inc. (the "Company" or "OSI Systems") (NASDAQ: OSIS) today announced that its Optoelectronics division has received an order for approximately $4 million from a leading defense electronics original equipment manufacturer (OEM) to provide optical sensors.
- 08/14/2020
|
Is OSI Systems, Inc.'s (NASDAQ:OSIS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
- OSI Systems' (NASDAQ:OSIS) stock is up by a considerable 14% over the past three months. As most would know...
- 08/11/2020
|
OSI Systems, Inc.'s (NASDAQ:OSIS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
- OSI Systems' (NASDAQ:OSIS) stock is up by a considerable 14% over the past three months. As most would know...
- 08/11/2020
|
OSI Systems Announces Fourth Quarter and Fiscal Year End Conference Call
- OSI Systems, Inc. (Nasdaq: OSIS) today announced that it will hold its quarterly conference call on Thursday, August 20, 2020 at 1:30pm PT to discuss its results for the fourth quarter and fiscal year ended June 30, 2020.
- 08/11/2020
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- 08/07/2020
|
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -10.34% and 16.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020, and provided a business update.
- 08/06/2020
|
Did Hedge Funds Make The Right Call On Insmed Incorporated (INSM)?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
OSI Systems Receives $5 Million Order to Provide Medical Sensors
- OSI Systems, Inc. (the "Company" or "OSI Systems") (NASDAQ: OSIS) today announced that its Optoelectronics division has received an order for approximately $5 million from a leading healthcare original equipment manufacturer (OEM) to provide optical sensors for use in medical devices.
- 07/28/2020
|
OSI Systems Awarded $5 Million Contract to Develop Automated Detection of Biosecurity Risk Items
- OSI Systems, Inc. (the "Company" or "OSI Systems") (NASDAQ: OSIS) today announced that its Security division was awarded a contract from the Commonwealth Government of Australia represented through the Department of Agriculture, Water and the Environment ("DAWE") for approximately $5 million for the supply of Rapiscan® RTT®110 hold baggage screening systems and the development and delivery of software algorithms for the automated detection of biosecurity risk items.
- 07/27/2020
|
Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2020 financial results on Thursday, August 6, 2020.
- 07/27/2020
|
A Quick Analysis On Insmed's (NASDAQ:INSM) CEO Salary
- This article will reflect on the compensation paid to Will Lewis who has served as CEO of Insmed Incorporated...
- 07/24/2020
|
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- 07/24/2020
|
Steven Cohen Homes in on Otonomy by Expanding Stake
- Guru ups bet in biotech focused on ear-related disorders Continue reading...
- 07/15/2020
|
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that ARIKAYCE® (amikacin liposome inhalation suspension) has been included in the new international treatment guidelines for nontuberculous mycobacterial (NTM) lung disease, a chronic, debilitating condition that can cause severe, permanent damage to the lungs. The evidence-based guidelines, issued by the American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA), recommend the use of ARIKAYCE for the treatment of patients with refractory NTM lung disease caused by Mycobacterium avium complex (MAC) as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- 07/07/2020
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- 07/06/2020
|
Non-Cystic Fibrosis Bronchiectasis (NCFB) - 2020 Pipeline Insight Report - ResearchAndMarkets.com
|
OSI Systems Receives $60 Million in Orders to Provide Cargo Inspection Systems and Services
- OSI Systems, Inc. (the "Company" or "OSI Systems") (NASDAQ: OSIS) today announced that its Security division received orders valued at approximately $60 million from a U.S. customer to provide several platforms of its cargo inspection systems and solutions, related upgrades, integration and maintenance services.
- 06/29/2020
|
Hedge Funds Are Dumping OSI Systems, Inc. (OSIS)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- 06/28/2020
|
Acceleron's Sotatercept Trial, And Other News: The Good, Bad And Ugly Of Biopharma
- Acceleron's sotatercept phase 2 trial yields positive data. Insmed reports positive phase 2 data from the WILLOW study. Chiasma's Mycapssa capsules get FDA appr
- 06/28/2020
|
Two Sigma Investments LP Sells 5,241 Shares of Insmed Incorporated (NASDAQ:INSM)
- Two Sigma Investments LP lessened its holdings in Insmed Incorporated (NASDAQ:INSM) by 10.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,555 shares of the biopharmaceutical company’s stock after selling 5,241 shares during the quarter. Two Sigma Investments LP […]
- 06/25/2020
|
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the Phase 2 WILLOW study of brensocatib (formerly INS1007) in patients with non-cystic fibrosis bronchiectasis (NCFBE) were presented during a virtual American Thoracic Society (ATS) session titled Breaking News: Clinical Trial Results in Pulmonary Medicine. Brensocatib is a novel, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases.
- 06/24/2020
|
Foresite Capital Management IV LLC Has $10.87 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM)
- Foresite Capital Management IV LLC reduced its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 52.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 678,322 shares of the biopharmaceutical company’s stock after selling 751,196 shares during the period. Insmed comprises approximately 13.0% of Foresite Capital Management […]
- 06/24/2020
|
NI woman opens up about CF battle and helping others after surviving ICU
- The Newtownabbey woman is giving something back with new clothing brand '65 roses'
- 06/21/2020
|
Is Insmed Incorporated (INSM) Going to Burn These Hedge Funds?
- In this article we will take a look at whether hedge funds think Insmed Incorporated (NASDAQ:INSM) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]
- 06/19/2020
|
Sphingotec's Critical Care Biomarkers Early Diagnose Risk of Loss of Endothelial, Kidney and Heart Function in Severely Ill COVID-19 Patients | | IT Business Net
- Results of a consensus meeting of clinical experts investigating sphingotec's diagnostic solutions for acute and critical care in COVID-19. sphingotec's biomarkers penKid, bio-ADM, and DPP3
- 06/18/2020
|
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing exacerbations. Brensocatib is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) currently being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases.
- 06/08/2020
|
Edited Transcript of INSM earnings conference call or presentation 30-Apr-20 12:30pm GMT
- Q1 2020 Insmed Inc Earnings Call
- 06/06/2020
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to five new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- 06/05/2020
|
Insmed to Present at Two June Conferences
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the following virtual investor conferences:
- 05/26/2020
|
A Look At The Intrinsic Value Of OSI Systems, Inc. (NASDAQ:OSIS)
- In this article we are going to estimate the intrinsic value of OSI Systems, Inc. (NASDAQ:OSIS) by taking the expected...
- 05/25/2020
|
Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new data from the Phase 2 WILLOW study of brensocatib (formerly known as INS1007) in non-cystic fibrosis bronchiectasis (NCFBE) will be presented during a virtual clinical trials session hosted by the American Thoracic Society (ATS) on Wednesday, June 24, 2020, at 2:00 pm ET. Data will be presented by lead study investigator James Chalmers, MBChB, Ph.D., Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee, UK. Insmed will hold a conference call following the oral session during which Professor Chalmers will further discuss the WILLOW data and Insmed management will provide a business assessment of brensocatib.
- 05/20/2020
|
Billionaire Steven Cohen Bets Big on These 3 Stocks
- And they’re off to the races. All three of the major U.S. stock indexes popped on Monday after biotech company Moderna reported its experimental COVID-19 vaccine produced encouraging results in its Phase 1 trial, with it appearing to be safe and able to generate an immune response against the virus.While the news has inspired optimism among market watchers, one investing guru is saying slow your roll. Billionaire Steve Cohen told the employees of his investment firm, Point72 Asset Management, to use caution amid the market’s slight rebounds from low points.In a note to his staff, Cohen wrote, “Markets don’t come back in a straight line; after an earthquake there are tremors. We need to continue to be disciplined. We are seeing plenty of opportunities to generate returns, but I don’t want us taking undue risks.”Using what’s known as a multi-strategy approach which involves stock market investments as well as global investments in several asset classes all at once based on macroeconomic trends, Cohen is considered one of the best in the business. The legendary stock picker has the track record to back up his reputation.Taking a page from Cohen’s playbook, we scanned a recent 13F filing disclosing Point72’s recent buys and found three healthcare stocks that looked promising. After running each through TipRanks’ database, we learned that some Wall Street analysts are also avid fans of the Buy-rated tickers.Verastem (VSTM)Targeting the critical signaling pathways in cancer, Verastem is developing a diverse portfolio of small molecule drugs that could potentially stop the disease in its tracks. Based on this pipeline that includes phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) inhibitors, some see significant gains in VSTM’s future. Cohen is among those that have high hopes for this healthcare name. Pulling the trigger on VSTM for the first time, Point72 purchased more than 6.1 million shares. The value of the firm’s new holding comes in at over $16 million.Meanwhile, five-star analyst Alethia Young, of Cantor Fitzgerald, cites recently released data on VS-6766 and Defactinib in ovarian and non-small-cell lung carcinoma (NSCLC) as the major component of her bullish thesis. For ovarian cancer, a 67% response rate was seen in six patients in the KRAS subgroup.The candidate also demonstrated activity in a subgroup of NSCLC KRAS G12V patients, with it producing a 10% response rate in the overall KRAS group of ten patients treated in the combo study. This suggests that G12V was the main driver of the effect. Young added, “In addition to the investigator run NSCLC cohort, VSTM studied G12V in another seven patients achieving a 57% ORR.” Additionally, while toxicities related to MEK/RAF and FAK were expected, the go forward dose appeared to be tolerable.Expounding on the implications of the data, Young said, “We find these data encouraging based on current market cap size since they have found likely two indications in subgroups where the monotherapy or combinations are active. We wonder if there will be questions around not seeing activity in the broader KRAS NSCLC subgroup, but overall we think this early signal in a hard to treat KRAS subgroup population is positive.”It should also be noted that challenging experiences with PI3K delta have created some headwinds, but Young still thinks the commercial potential for these therapies is underappreciated by investors. “Verastem’s Copiktra is approved for CLL and FL/SLL, which are two large markets. Our doctor checks suggest that PI3K is a viable class certainly in relapsed or refractory patients,” she stated.Bearing this in mind, Young left an Overweight rating and $6 price target on the stock. Should this target be met, a twelve-month gain of 233% could be in store. (To watch Young’s track record, click here)Looking at the consensus breakdown, 2 Buys and 1 Hold add up to a Moderate Buy analyst consensus. At $4.50, the average price target implies nearly 149% upside potential. (See Verastem stock analysis on TipRanks)Amicus Therapeutics (FOLD)Focused on delivering high-quality therapies for people living with rare metabolic diseases, Amicus Therapeutics takes its place at the forefront of the space. With a jam-packed development pipeline, it’s no wonder FOLD has scored fans. Cohen’s firm just gave the healthcare stock a nod of approval. Acquiring a new FOLD holding, Point72 picked up 2,242,900 shares valued at $20,724,000.Turning now to the analyst community, FOLD has received significant support. One of the analysts in its corner is Leerink's Joseph Schwartz, who points out that despite the COVID-19 pandemic, FOLD exceeded expectations for Q1 2020 revenue thanks to high pt. demand. The five-star analyst also noted, “Favorable reimbursement dynamics also continued to tailwinds for Galafold sales in Q1 2020. As strong adoption of Galafold continues, FOLD management reiterated that revenue continues to track towards full-year 2020 guidance of $250 to $260 million.”Additionally, Schwartz argues that in the last year, FOLD has increased its focus on cost management while still remaining committed to developing its product candidates, helping the company “turn a corner.” As part of this strategy, more cost saving initiatives have been put in place to mitigate any impacts from COVID-19, allowing its cash runway to extend through the second half of 2022.Most exciting for Schwartz, though, is that Phase 3 PROPEL for AT-GAA, its “crown jewel”, remains on track and manufacturing and supply is intact globally. Adding to the good news, AT-GAA was granted a rolling BLA submission, which is set to start in the second half of this year. This means that top-line data could be released in the first half of 2021.As the development of FOLD’s gene therapy portfolio is also progressing, with it planning to have clinical development, manufacturing and regulatory discussions for both the CLN6 and CLN3 Battens gene therapy programs, the deal is sealed for Schwartz.To this end, Schwartz maintained an Outperform call and $19 price target. This target conveys his confidence in FOLD’s ability to climb 51% higher in the next year. (To watch Schwartz’s track record, click here)What does the rest of the Street think about FOLD? It turns out that other analysts also have high hopes. With 5 Buys and a single Hold, the word on the Street is that this stock is a Strong Buy. In addition, the $20.58 average price target puts the upside potential at 65%. (See Amicus stock analysis on TipRanks)Insmed (INSM)Last but not least we have Insmed, which works on developing effective therapies for patients suffering from serious and rare diseases. While COVID-19 has weighed on the company, there are major catalysts on the horizon that could potentially fuel upside for shares.Point72 takes its place on the bulls’ side. Boosting its holding by a whopping 1,283%, the firm snapped up 3.3 million shares. As for the value of this new addition, it lands at $53.4 million.Like Cohen, H.C. Wainwright analyst Andrew Fein is optimistic. “In spite of investor uncertainty associated the with COVID-19 pandemic, we view the apparent progression of all pipeline programs in lieu of such headwinds as positive for the stock,” Fein commented.Looking specifically at ARIKAYCE, growth has slowed as a result of the public health crisis, but the five-star analyst argues that several factors suggest the momentum for sales growth will persist. These include the submission of an NDA in March in Japan, which boasts the largest diagnosed MAC lung disease population, and the pending EU marketing authorization. This would set INSM up for a Germany launch by year-end, followed up by a UK launch shortly after.The most noteworthy potential catalyst in terms of prescriptions and determining treatment duration, though, will be updated guidelines from both the American Thoracic Society (ATS) and the Infectious Disease Society of America (IDSA). It also doesn’t hurt that there’s a peer-reviewed paper offering solutions to address the adverse events that are sometimes witnessed with ARIKAYCE use and a patient reported outcome (PRO) tool for ARIKAYCE in non-tuberculosis (NTM) disease is being developed, with the trial kicking off in the beginning of the second half of 2020.Fein added, “Insmed announced that it has not yet observed any disruptions in the supply chain for ARIKAYCE production and should be able to meet global demand through 2022...Insmed believes that the current climate is causing a bolus of patients, which could lead to a major upswing in patients being treated with ARIKAYCE in 2H20.”If that wasn’t enough, Brensocatib, formerly INS1007, is on a clear path to Phase 3 trial initiation in bronchiectasis and is being studied in severe COVID-19 patients. “We feel the development of Brensocatib remains promising as we recall the announcement that AstraZeneca decided to exercise the first option to advance Brensocatib development in chronic obstructive pulmonary disease (COPD) or asthma patients,” Fein noted. Treprostinil Palmitil, previously INS1009, could also see Phase 1 initiation in pulmonary arterial hypertension in the second half of 2020.Based on all of the above, Fein reiterated his Buy rating and $52 price target. Given this target, shares could skyrocket 103% in the next twelve months. (To watch Fein’s track record, click here)With only Buy ratings assigned in the last three months, 6 to be exact, the message is clear: INSM is a Strong Buy. The $47.83 average price target is less aggressive than Fein’s, but it still leaves room for 87% upside potential. (See Insmed stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 05/19/2020
|
Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced public offering of 11,155,000 shares of its common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares, at a public offering price of $23.25 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, were approximately $259.4 million.
- 05/07/2020
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- 05/07/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks hitting 52-week highs May 5.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) (announced a partnership with Catalent Inc (NYSE: CTLT) for manufacturing of a vaccine against the novel coronavirus) * BIO-TECHNE Corp (NASDAQ: TECH) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * ChemoCentryx Inc (NASDAQ: CCXI) * DexCom, Inc. (NASDAQ: DXCM) (received Health Canada temporary authorization for its Dexcom G6 CGM for use in hospitals to monitor critically ill patients during COVID-19 pandemic) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) (announced FDA approval for Johnson & Johnson (NYSE: JNJ) Janssen unit's subcutaneous formulation of Darzalex, which uses Halozyme's Enhanze technology, in treating multiple myeloma) * Imara Inc (NASDAQ: IMRA) * Immunomedics, Inc. (NASDAQ: IMMU) (announced the commercial availability of its recently-approved breast cancer drug Trodelvy in the U.S.) * Masimo Corporation (NASDAQ: MASI) * Minerva Neurosciences Inc (NASDAQ: NERV) * Vermillion, Inc. (NASDAQ: VRML) * Zynex Inc. (NASDAQ: ZYXI)None of the biotech/medical devices/diagnostics company hit 52-week lows Monday.Stocks In Focus Adverum's Gene Therapy Shows Robust Efficacy, Safety In Phase 1 Study For Wet Age-Related Macular Degeneration Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new interim clinical data from Cohorts 1-3 of the OPTIC Phase 1 dose-ranging clinical study of single-dose of ADVM-022 intravitreal injection gene therapy in patients with wet age-related macular degeneration, which further demonstrated the transformative potential of ADVM-022 to greatly reduce anti-VEGF injection burden in wet AMD."It's impressive to see the long-term durability demonstrated at the higher dose of ADVM-022 in a patient population that previously required frequent injections to maintain their vision and are now beyond one year of follow-up with no rescue injections," Arshad Khanani, the study's principal investigator, said in a statement.The company also offered a business update, reporting cash, cash equivalents and short-term investments of $297 million as of March 31. Adverum said it expects to submit a NDA for ADVM-022 in diabetic retinopathy in the first half of 2020 and present data from all four cohorts of the OPTIC trial in the second half.Bio-Rad Droplet Digital PCR Test Kit For Coronavirus Receives EUA Bio-Rad said its SARS-CoV-2 Droplet Digital PCR test kit has been granted Emergency Use Authorization by the FDA. The SARS-CoV-2 Droplet Digital PCR test runs on Bio-Rad's QX200 and QXDx ddPCR systems.Chembio's Serological Test For Coronavirus Gets CE Marking Chembio Diagnostics Inc (NASDAQ: CEMI) said it has attained the CE Marking for its DPP COVID-19 System. The CE Marking allows the company commercialize the system within the member states of the European Union and the Caribbean region, except for Puerto Rico.The DPP COVID-19 System is a serological test and analyzer that provides numerical readings for both IgM and IgG antibody levels within 15 minutes from a simple finger stick drop of blood. The test has received EUA in the U.S.Separately, the company reported first-quarter results, showing a 20% decline in revenue to $6.9 million and a wider net loss of 29 cents per share.In premarket trading Tuesday, the stock was gaining 17.47% to $14.39.View more earnings on IBBSee also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Regeneron, Sanofi Say PD-1 Inhibitor Libtayo Found Effective In Skin Cancer In Pivotal Study Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced top-line data from a pivotal, single-arm, open-label trial of PD-1 inhibitor Libtayo in patients with advanced basal cell carcinoma who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy. The data showed the investigational asset demonstrated clinically meaningful and durable responses in this group of patients for whom there are currently no approved treatments.The companies said they plan regulatory submissions in 2020.Libtayo was approved in September 2018 by the FDA to treat patients with metastatic cutaneous squamous cell carcinoma.Insmed Announces Secondary Offering Of Common Stock Insmed Incorporated (NASDAQ: INSM) said it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares are being offered by the company.The stock was down 0.84% at $24.65 in Tuesday's premarket session.Earnings GenMark Diagnostics, Inc (NASDAQ: GNMK) announced first-quarter revenue of $38.7 million, in line with the number it mentioned in its April 8 pre-announcement and representing an 80% year-over-year increase. The loss per share narrowed from 21 cents to 12 cents, while analysts estimated a loss of 14 cents per share.The company raised its full-year revenue guidance to $120 million to $130 million, ahead of the $108.58-million consensus estimate, and it also increased its gross margin guidance to 38-40%.Separately, GenMark announced the appointment of Scott Mendel as CEO. Mendel has been serving as CEO on an interim basis since February.The stock was up 13.29% at $13.30 in the premarket session.On The Radar Earnings * Oxford Immunotec Global PLC (NASDAQ: OXFD) (before the market open) * Karyopharm Therapeutics Inc (NASDAQ: KPTI) (before the market open) * Haemonetics Corporation (NYSE: HAE) (before the market open) * Antares Pharma Inc (NASDAQ: ATRS) (before the market open) * Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open) * Vericel Corp (NASDAQ: VCEL) (before the market open) * Regeneron * Neuronetics Inc (NASDAQ: STIM) (before the market open) * Mallinckrodt PLC (NYSE: MNK) (before the market open) * Akebia Therapeutics Inc (NASDAQ: AKBA) (before the market open) * Agile Therapeutics Inc (NASDAQ: AGRX) (after the market close) * Aquestive Therapeutics Inc (NASDAQ: AQST) (after the market close) * Akcea Therapeutics Inc (NASDAQ: AKCA) (after the market close) * Acorda Therapeutics Inc (NASDAQ: ACOR) (after the market close) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (after the market close) * Synthetic Biologics Inc (NYSE: SYN) (after the market close) * T2 Biosystems Inc (NASDAQ: TTOO) (after the market close) * Iovance Biotherapeutics Inc (NASDAQ: IOVA) (after the market close) * MacroGenics Inc (NASDAQ: MGNX) (after the market close) * Zogenix, Inc. (NASDAQ: ZGNX) (after the market close) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the market close) * Exelixis, Inc. (NASDAQ: EXEL) (after the market close) * Myriad Genetics, Inc. (NASDAQ: MYGN) (after the market close) * Inspire Medical Systems Inc (NYSE: INSP) (after the market close) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) (after the market close) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) (after the market close) * Nevro Corp (NYSE: NVRO) (after the market close) * Clovis Oncology Inc (NASDAQ: CLVS) (after the market close) * InVitae Corp (NYSE: NVTA) (after the market close) * Cytosorbents Corp (NASDAQ: CTSO) (after the market close) * Cardiovascular Systems Inc (NASDAQ: CSII) (after the market close) * Cerus Corporation (NASDAQ: CERS) (after the market close) * Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) (after the market close) * Incyte Corporation (NASDAQ: INCY) (after the market close) * Orthopediatrics Corp (NASDAQ: KIDS) (after the market close)Related Link: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace See more from Benzinga * The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/05/2020
|
Insmed Announces Pricing of Public Offering of Common Stock
- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public of $23.25 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $225.5 million. In addition, Insmed has granted the underwriters a 30-day option to purchase up to an additional 1,455,000 shares of common stock.
- 05/05/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
Insmed Announces Proposed Public Offering of Common Stock
- Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Insmed. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 05/04/2020
|
Insmed Incorporated (NASDAQ:INSM) Just Reported And Analysts Have Been Cutting Their Estimates
- As you might know, Insmed Incorporated (NASDAQ:INSM) recently reported its first-quarter numbers. It looks like a...
- 05/04/2020
|
Insmed (INSM) Q1 2020 Earnings Call Transcript
- INSM earnings call for the period ending March 31, 2020.
- 05/01/2020
|
H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
- H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM) today and set a price target of $52.00. The company's shares closed last
- 05/01/2020
|
H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
- H.C. Wainwright analyst
Andrew Fein
maintained a
Buy
rating on Insmed (
INSM
–
Research Report
) today and set a price target of
$52.00
. The company’s shares closed last Thursday at $23.00.
According to
TipRanks.com
, Fein is a 5-star analyst with a
- 05/01/2020
|
Edited Transcript of INSM earnings conference call or presentation 30-Apr-20 12:30pm GMT
- Q1 2020 Insmed Inc Earnings Call
- 05/01/2020
|
Insmed Incorporated (INSM) CEO Will Lewis on Q1 2020 Results - Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM) Q1 2020 Results Conference Call April 30, 2020 08:30 AM ET Company Participants Sara Bonstein - CFO Will Lewis - Chairman and
- 04/30/2020
|
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -10.45% and 9.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 04/30/2020
|
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -10.45% and 9.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 04/30/2020
|
Recap: Insmed Q1 Earnings
- Shares of Insmed (NASDAQ:INSM) were unchanged at $21.05 after the company reported Q1 results.Quarterly Results Earnings per share increased 22.92% year over year to ($0.74), which missed the estimate of ($0.71).Revenue of $36,860,000 higher by 68.30% from the same period last year, which beat the estimate of $34,800,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Apr 30, 2020View more earnings on INSMTime: 11:01 AM ETWebcast URL: https://www.webcaster4.com/Webcast/Page/2000/34294Recent Stock Performance 52-week high: $34.94Company's 52-week low was at $12.09Price action over last quarter: down 20.02%Company Description Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.See more from Benzinga * Recap: Patrick Industries Q1 Earnings * Superior Group: Q1 Earnings Insights * Recap: Independent Bank Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 04/30/2020
|
Analysts Expect Breakeven For Insmed Incorporated (NASDAQ:INSM)
- Insmed Incorporated's (NASDAQ:INSM): Insmed Incorporated, a biopharmaceutical company, focuses on the development and...
- 04/30/2020
|
Insmed: 1Q Earnings Snapshot
- BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Thursday reported a loss of $66.4 million in its first quarter.
On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 74 cents.
The results missed Wall Street expectations
- 04/30/2020
|
Insmed Reports First Quarter 2020 Financial Results and Provides Business Update
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2020, and provided a business update.
- 04/30/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Class A Common Stock(NYSE: BIO) • Capricor
- 04/30/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 29)
• Arvinas Inc (NASDAQ...
- 04/30/2020
|
Notable earnings before Thursday's open
- AAL, ABMD, AGIO, AIMC, AIT, AMRN, ARW, ASPS, AUY, BAX, BC, BEN, BPOP, CFR, CG, CHD, CI, CMCSA, COLB, COP, COR, CRS, CWT, DAN, DNKN, DOW, EME, ESI, ETN, FBP, FCN, FLWS, GNRC, GRA, GT, HBI, HGV, HUBB, I
- 04/29/2020
|
Why Insmed (INSM) Might Surprise This Earnings Season
- Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/29/2020
|
Why Insmed (INSM) Might Surprise This Earnings Season
- Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/29/2020
|
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
- The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s (NASDAQ: IMMU) breast cancer drug snagging an FDA nod and Sanofi SA's (NASDAQ: SNY) meningococcal
- 04/26/2020
|
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/23/2020
|
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
- Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/23/2020
|
BRIEF-Brensocatib To Be Studied In Patients With Severe COVID-19 In Investigator-Initiated Trial
|
Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will provide funding and clinical drug supply for the STOP-COVID19 (Superiority Trial of Protease inhibition in COVID-19) trial, an investigator-initiated study of brensocatib (formerly known as INS1007) in up to 300 hospitalized patients with COVID-19 sponsored by the University of Dundee. The study, which has been prioritized and designated an Urgent Public Health trial by the UK's National Institute for Health Research, is expected to begin enrollment in May 2020.
- 04/23/2020
|
Insmed (NASDAQ:INSM) Raised to "Sell" at BidaskClub
- Insmed (NASDAQ:INSM) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Thursday, BidAskClub reports. Several other analysts also recently issued reports on the company. Zacks Investment Research raised Insmed from a “sell” rating to a “hold” rating in a research note […]
- 04/23/2020
|
Insmed (INSM) to Release Earnings on Thursday
- Insmed (NASDAQ:INSM) will issue its quarterly earnings data before the market opens on Thursday, April 30th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Insmed (NASDAQ:INSM) last announced its quarterly earnings data on […]
- 04/23/2020
|
Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2020 financial results on Thursday, April 30, 2020.
- 04/20/2020
|
Cubist Systematic Strategies LLC Has $123,000 Holdings in Insmed Incorporated (NASDAQ:INSM)
- Cubist Systematic Strategies LLC lessened its position in shares of Insmed Incorporated (NASDAQ:INSM) by 73.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,148 shares of the biopharmaceutical company’s stock after selling 14,152 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Insmed were worth $123,000 […]
- 04/18/2020
|
Bank of America Corp DE Lowers Holdings in Insmed Incorporated (NASDAQ:INSM)
- Bank of America Corp DE decreased its position in Insmed Incorporated (NASDAQ:INSM) by 98.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 106,073 shares of the biopharmaceutical company’s stock after selling 7,053,881 shares during the period. Bank of America Corp DE owned 0.12% of Insmed […]
- 04/18/2020
|
Q1 2020 EPS Estimates for Insmed Incorporated (NASDAQ:INSM) Lowered by Analyst
- Insmed Incorporated (NASDAQ:INSM) – SVB Leerink dropped their Q1 2020 earnings per share estimates for shares of Insmed in a research report issued to clients and investors on Wednesday, April 15th. SVB Leerink analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($0.60) per share for the quarter, down from their […]
- 04/18/2020
|
Insmed (INSM) Gets a Buy Rating from Morgan Stanley
- Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Insmed (INSM) today and set a price target of $35.00. The company's shares closed last
- 04/15/2020
|
Insmed (INSM) Gets a Buy Rating from Morgan Stanley
- Morgan Stanley analyst
Matthew Harrison
maintained a
Buy
rating on Insmed (
INSM
–
Research Report
) today and set a price target of
$35.00
. The company’s shares closed last Wednesday at $17.38.
According to
TipRanks.com
, Harrison is a 5-star analy
- 04/15/2020
|
Alliancebernstein L.P. Grows Stake in Insmed Incorporated (NASDAQ:INSM)
- Alliancebernstein L.P. lifted its position in Insmed Incorporated (NASDAQ:INSM) by 11.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 118,700 shares of the biopharmaceutical company’s stock after buying an additional 11,800 shares during the period. Alliancebernstein L.P. owned approximately 0.13% […]
- 04/14/2020
|
Brokerages Anticipate Insmed Incorporated (NASDAQ:INSM) Will Post Quarterly Sales of $37.32 Million
- Wall Street brokerages expect that Insmed Incorporated (NASDAQ:INSM) will report sales of $37.32 million for the current quarter, Zacks reports. Three analysts have made estimates for Insmed’s earnings, with the highest sales estimate coming in at $46.50 million and the lowest estimate coming in at $29.90 million. Insmed reported sales of $21.90 million in the […]
- 04/14/2020
|
Is Insmed (NASDAQ:INSM) A Risky Investment?
- Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- 04/13/2020
|
Geode Capital Management LLC Grows Holdings in Insmed Incorporated (NASDAQ:INSM)
- Geode Capital Management LLC raised its position in shares of Insmed Incorporated (NASDAQ:INSM) by 4.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,215,211 shares of the biopharmaceutical company’s stock after purchasing an additional 46,915 shares during the quarter. Geode Capital Management […]
- 04/12/2020
|
Zacks: Brokerages Expect Insmed Incorporated (NASDAQ:INSM) Will Post Earnings of -$0.63 Per Share
- Wall Street analysts expect Insmed Incorporated (NASDAQ:INSM) to announce earnings per share (EPS) of ($0.63) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Insmed’s earnings, with estimates ranging from ($0.80) to ($0.53). Insmed reported earnings per share of ($0.94) during the same quarter last year, which would suggest […]
- 04/12/2020
|
Should You Be Pleased About The CEO Pay At Insmed Incorporated’s (NASDAQ:INSM)
- In 2012 Will Lewis was appointed CEO of Insmed Incorporated (NASDAQ:INSM). First, this article will compare CEO...
- 04/09/2020
|
Were Hedge Funds Right About Gray Television, Inc. (GTN)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/09/2020
|
Franklin Resources Inc. Has $16.76 Million Holdings in Insmed Incorporated (NASDAQ:INSM)
- Franklin Resources Inc. raised its stake in Insmed Incorporated (NASDAQ:INSM) by 6.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 701,800 shares of the biopharmaceutical company’s stock after acquiring an additional 39,700 shares during the quarter. Franklin Resources Inc. owned about 0.78% […]
- 04/08/2020
|
Hedge Funds Have Never Been This Bullish On Eidos Therapeutics, Inc. (EIDX)
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/07/2020
|
Do Hedge Funds Love Freshpet Inc (FRPT)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/07/2020
|
Is Sally Beauty Holdings, Inc. (SBH) Going to Burn These Hedge Funds?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/07/2020
|
Hedge Funds Are Crazy About Insmed Incorporated (INSM)
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/07/2020
|
Insmed Incorporated (NASDAQ:INSM) Shares Sold by AQR Capital Management LLC
- AQR Capital Management LLC cut its stake in Insmed Incorporated (NASDAQ:INSM) by 13.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,075 shares of the biopharmaceutical company’s stock after selling 11,281 shares during the quarter. AQR Capital Management LLC owned approximately 0.08% […]
- 04/06/2020
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 13 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- 04/03/2020
|
Insmed (NASDAQ:INSM) Lowered to Strong Sell at BidaskClub
- Insmed (NASDAQ:INSM) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday, BidAskClub reports. Several other equities research analysts have also recently issued reports on INSM. Credit Suisse Group lowered their target price on shares of Insmed from $49.00 to […]
- 04/03/2020
|
BRIEF-Insmed Appoints Carol A. Schafer To Its Board Of Directors
|
Insmed Appoints Carol A. Schafer to its Board of Directors
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets, and currently serves as a Managing Partner at Hyphen Advisors, LLC.
- 04/02/2020
|
Insmed Incorporated (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Analysts
- Shares of Insmed Incorporated (NASDAQ:INSM) have been assigned an average recommendation of “Buy” from the eleven research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average […]
- 04/02/2020
|
Great West Life Assurance Co. Can Invests $133,000 in Insmed Incorporated (NASDAQ:INSM)
- Great West Life Assurance Co. Can bought a new stake in shares of Insmed Incorporated (NASDAQ:INSM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,611 shares of the biopharmaceutical company’s stock, valued at approximately $133,000. Other hedge funds and other institutional investors have […]
- 03/29/2020
|
Amalgamated Bank Grows Stake in Insmed Incorporated (NASDAQ:INSM)
- Amalgamated Bank boosted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 18.1% during the 4th quarter, HoldingsChannel reports. The firm owned 16,245 shares of the biopharmaceutical company’s stock after buying an additional 2,491 shares during the period. Amalgamated Bank’s holdings in Insmed were worth $388,000 at the end of the most recent quarter. Other […]
- 03/29/2020
|
Dynamic Technology Lab Private Ltd Makes New $258,000 Investment in Insmed Incorporated (NASDAQ:INSM)
- Dynamic Technology Lab Private Ltd purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,791 shares of the biopharmaceutical company’s stock, valued at approximately $258,000. Other hedge funds and […]
- 03/26/2020
|
Insmed (NASDAQ:INSM) Stock Rating Lowered by ValuEngine
- Insmed (NASDAQ:INSM) was downgraded by research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued on Tuesday, ValuEngine reports. Other equities research analysts also recently issued research reports about the company. Morgan Stanley boosted their target price on Insmed from $37.00 to $50.00 and gave the stock an […]
- 03/24/2020
|
Insmed (INSM) Gets a Buy Rating from H.C. Wainwright
- In a report issued on March 17, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed (INSM –
- 03/22/2020
|
Zacks: Brokerages Anticipate Insmed Incorporated (NASDAQ:INSM) to Post -$0.63 Earnings Per Share
- Wall Street brokerages expect Insmed Incorporated (NASDAQ:INSM) to announce earnings of ($0.63) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Insmed’s earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.80). Insmed posted earnings per share of ($0.94) during the same quarter last year, which […]
- 03/22/2020
|
Insmed Incorporated (NASDAQ:INSM) Shares Sold by Alyeska Investment Group L.P.
- Alyeska Investment Group L.P. lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 46.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 143,765 shares of the biopharmaceutical company’s stock after selling 124,654 shares during the quarter. Alyeska Investment […]
- 03/20/2020
|
Insmed (NASDAQ:INSM) Shares Down 7.2% After Analyst Downgrade
- Insmed Incorporated (NASDAQ:INSM) traded down 7.2% during trading on Wednesday after Stifel Nicolaus lowered their price target on the stock from $55.00 to $45.00. Stifel Nicolaus currently has a buy rating on the stock. Insmed traded as low as $12.70 and last traded at $14.39, 1,524,809 shares traded hands during trading. An increase of 8% […]
- 03/20/2020
|
Is Insmed (NASDAQ:INSM) Weighed On By Its Debt Load?
- Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
ProShare Advisors LLC Has $749,000 Position in Insmed Incorporated (NASDAQ:INSM)
- ProShare Advisors LLC cut its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 8.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,383 shares of the biopharmaceutical company’s stock after selling 2,907 shares during the quarter. ProShare Advisors LLC’s holdings in Insmed were […]
- 03/18/2020
|
Insmed (INSM) Gets a Buy Rating from Credit Suisse
- In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on Insmed (INSM), with a price target of $42.00. The company's
- 03/17/2020
|
Insmed (INSM) Gets a Buy Rating from Credit Suisse
- In a report released yesterday,
Martin Auster
from Credit Suisse maintained a
Buy
rating on Insmed (
INSM
–
Research Report
), with a price target of
$42.00
. The company’s shares closed last Monday at $14.85, close to its 52-week low of $12.09.
Acco
- 03/17/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps (Biotech stocks that hit 52-week lows March 16.) * 89bio Inc (NASDAQ: ETNB) * Abbott Laboratories (NYSE: ABT) * Abeona Therapeutics Inc (NASDAQ: ABEO) * ABIOMED, Inc. (NASDAQ: ABMD) * AC Immune SA (NASDAQ: ACIU) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Achieve Life Sciences Inc (NASDAQ: ACHV) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adamis Pharmaceuticals Corp (NASDAQ: ADM) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Affimed NV (NASDAQ: AFMD) * Aimmune Therapeutics Inc (NASDAQ: AIMT) (announced potential slow uptake of its peanut allergy drug due to COVID-19) * Akari Therapeutics PLC (NASDAQ: AKTX) * Akcea Therapeutics Inc (NASDAQ: AKCA) * Akers Biosciences Inc (NASDAQ: AKER) * Akorn, Inc. (NASDAQ: AKRX) * Albireo Pharma Inc (NASDAQ: ALBO) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * Alkermes Plc (NASDAQ: ALKS) * Allena Pharmaceuticals Inc (NASDAQ: ALNA) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Alterity Therapeutics Ltd (NASDAQ: ATH) * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) * Amarin Corporation plc (NASDAQ: AMRN) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) * Anavex Life Sciences Corp (NASDAQ: AVXL) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * AngioDynamics, Inc. (NASDAQ: ANGO) * Anika Therapeutics Inc (NASDAQ: ANIK) * Antares Pharma Inc (NASDAQ: ATRS) * Applied DNA Sciences Inc (NASDAQ: APDN) * Applied Genetic Technologies Corp (NASDAQ: AGTC) * Aptinyx Inc (NASDAQ: APTX) * Aquestive Therapeutics Inc (NASDAQ: AQST) * Aravive Inc (NASDAQ: ARAV) * Arca Biopharma Inc (NASDAQ: ABIO) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Artelo Biosciences Inc (NASDAQ: ARTL) * AstraZeneca plc (NYSE: AZN) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Athenex Inc (NASDAQ: ATNX) * aTyr Pharma Inc (NASDAQ: LIFE) * Auris Medical Holding Ltd (NASDAQ: EARS) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * Avrobio Inc (NASDAQ: AVRO) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Baxter International Inc (NYSE: BAX) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) * Bio-Path Holdings Inc (NASDAQ: BPTH) * BIO-TECHNE Corp (NASDAQ: TECH) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * BIOFRONTERA AG/ADR (NASDAQ: BFRA) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BioLife Solutions Inc (NASDAQ: BLFS) * BIOLASE Inc (NASDAQ: BIOL) * BIOLINERX LTD/S ADR (NASDAQ: BLRX) * BioNano Genomics Inc (NASDAQ: BNGO) * BioSig Technologies Inc (NASDAQ: BSGM) * BioTelemetry Inc (NASDAQ: BEAT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * bluebird bio Inc (NASDAQ: BLUE) * Blueprint Medicines Corp (NASDAQ: BPMC) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Boston Scientific Corporation (NYSE: BSX) * Cabaletta Bio Inc (NASDAQ: CABA) * Cara Therapeutics Inc (NASDAQ: CARA) * Cardiovascular Systems Inc (NASDAQ: CSII) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) * Celcuity Inc (NASDAQ: CELC) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Cellectis SA (NASDAQ: CLLS) * CELYAD SA/ADR (NASDAQ: CYAD) * Cerecor Inc (NASDAQ: CERC) * Cerus Corporation (NASDAQ: CERS) * Champions Oncology Inc (NASDAQ: CSBR) * Chembio Diagnostics Inc (NASDAQ: CEMI) * China SXT Pharmaceuticals Inc (NASDAQ: SXTC) * CNS Pharmaceuticals Inc (NASDAQ: CNSP) * Coherus Biosciences Inc (NASDAQ: CHRS) * Conatus Pharmaceuticals Inc (NASDAQ: CNAT) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) * Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) * Crispr Therapeutics AG (NASDAQ: CRSP) * CTI BioPharma Corp (NASDAQ: CTIC) * Curis, Inc. (NASDAQ: CRIS) * CytomX Therapeutics Inc (NASDAQ: CTMX) * DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) * Dynavax Technologies Corporation (NASDAQ: DVAX) * Edap Tms SA (NASDAQ: EDAP) * Edesa Biotech Inc (NASDAQ: EDSA) * Editas Medicine Inc (NASDAQ: EDIT) * Edwards Lifesciences Corp (NYSE: EW) * Ekso Bionics Holdings Inc (NASDAQ: EKSO) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Elanco Animal Health Inc (NYSE: ELAN) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Esperion Therapeutics Inc (NASDAQ: ESPR) * Evogene Ltd (NASDAQ: EVGN) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * Exelixis, Inc. (NASDAQ: EXEL) * Exicure Inc (NASDAQ: XCUR) * Eyenovia Inc (NASDAQ: EYEN) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * FibroGen Inc (NASDAQ: FGEN) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Flexion Therapeutics Inc (NASDAQ: FLXN * Fresenius Medical Care AG & Co. (NYSE: FMS) * Fortress Biotech (NASDAQ: FBIO * FSD Pharma Inc (NASDAQ: HUGE) * G1 Therapeutics Inc (NASDAQ: GTHX) * Galera Therapeutics Inc (NASDAQ: GRTX) * Gamida Cell Ltd (NASDAQ: GMDA) * GENFIT S A/ADR (NASDAQ: GNFT) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Genocea Biosciences Inc (NASDAQ: GNCA) * Geron Corporation (NASDAQ: GERN) * GlaxoSmithKline plc (NYSE: GSK) * Globus Medical Inc (NYSE: GMED) * GlycoMimetics Inc (NASDAQ: GLYC) * Grifols SA - ADR ADR Class B (NASDAQ: GRFS) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Haemonetics Corporation (NYSE: HAE) * Hepion Pharmaceuticals Inc (NASDAQ: HEPA) * Heron Therapeutics Inc (NASDAQ: HRTX) * Hologic, Inc. (NASDAQ: HOLX) * Hookipa Pharma Inc (NASDAQ: HOOK) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * ImmuCell Corporation (NASDAQ: ICCC) * Immunic Inc (NASDAQ: IMUX) ) * Immunomedics, Inc. (NASDAQ: IMMU) * Imv Inc (NASDAQ: IMV) * Incyte Corporation (NASDAQ: INCY) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) * INmune Bio Inc (NASDAQ: INMB) * INNATE PHARMA S/S ADR (NASDAQ: IPHA) * Innoviva Inc (NASDAQ: INVA) * Intec Pharma Ltd (NASDAQ: NTEC) * Integra Lifesciences Holdings Corp (NASDAQ: IART * Intellia Therapeutics Inc (NASDAQ: NTLA) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Ionis Pharmaceuticals Inc (NASDAQ: IONS) * Iterum Therapeutics PLC (NASDAQ: ITRM) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Johnson & Johnson (NYSE: JNJ) * Kalvista Pharmaceuticals Inc (NASDAQ: KALV) * Kamada Ltd. (NASDAQ: KMDA) * KemPharm Inc (NASDAQ: KMPH) * Kindred Biosciences Inc (NASDAQ: KIN) * Kura Oncology Inc (NASDAQ: KURA) * Lantheus Holdings Inc (NASDAQ: LNTH) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * MacroGenics Inc (NASDAQ: MGNX) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Magenta Therapeutics Inc (NASDAQ: MGTA) * MannKind Corporation (NASDAQ: MNKD) * Mediwound Ltd (NASDAQ: MDWD) * Medtronic PLC (NYSE: MDT) * MEI Pharma Inc (NASDAQ: MEIP) * MeiraGTx Holdings PLC (NASDAQ: MGTX) * Menlo Therapeutics Inc (NASDAQ: MNLO) * MEREO BIOPHARMA/ADR (NASDAQ: MREO) * Mesoblast limited (NASDAQ: MESO) * Microbot Medical Inc (NASDAQ: MBOT) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) * Miragen Therapeutics Inc (NASDAQ: MGEN) * Misonix Inc (NASDAQ: MSON) * Moleculin Biotech Inc (NASDAQ: MBRX) * Monopar Therapeutics Inc (NASDAQ: MNPR) * Morphic Holding Inc (NASDAQ: MORF) * Morphosys Ag (NASDAQ: MOR) * Mylan NV (NASDAQ: MYL) * Myokardia Inc (NASDAQ: MYOK) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) * Nektar Therapeutics (NASDAQ: NKTR) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * NewLink Genetics Corp (NASDAQ: NLNK) * Novartis AG (NYSE: NVS) * Novus Therapeutics Inc (NASDAQ: NVUS) * NuVasive, Inc. (NASDAQ: NUVA) * Obseva SA (NASDAQ: OBSV) * Omeros Corporation (NASDAQ: OMER) * OncoSec Medical Inc (NASDAQ: ONCS) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) * OptiNose Inc (NASDAQ: OPTN) * Organovo Holdings Inc (NASDAQ: ONVO) * Orthofix Medical Inc (NASDAQ: OFIX) * Otonomy Inc (NASDAQ: OTIC) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Pacific Biosciences of California (NASDAQ: PACB) * Pacira Biosciences Inc (NASDAQ: PCRX) * Paratek Pharmaceuticals Inc (NASDAQ: PRTK) * Passage Bio Inc (NASDAQ: PASG) * PDS Biotechnology Corp (NASDAQ: PDSB) * Pfizer Inc. (NYSE: PFE) * PLx Pharma Inc (NASDAQ: PLXP) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precision BioSciences Inc (NASDAQ: DTIL) * Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) * Predictive Oncology Inc (NASDAQ: POAI) * Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) * ProQR Therapeutics NV (NASDAQ: PRQR) * Pulse Biosciences Inc (NASDAQ: PLSE) * PTC Therapeutics, Inc. (NASDAQ: PTCT) * Puma Biotechnology Inc (NASDAQ: PBYI) * Quest Diagnostics Inc (NYSE: DGX) * Radius Health Inc (NASDAQ: RDUS) * Regenxbio Inc (NASDAQ: RGNX) * Regulus Therapeutics Inc (NASDAQ: RGLS) * Replimune Group Inc (NASDAQ: REPL) * Revolution Medicines Inc (NASDAQ: RVMD) * Rexahn Pharmaceuticals, Inc.
- 03/17/2020
|
Bank of Montreal Can Has $673,000 Stock Holdings in Insmed Incorporated (NASDAQ:INSM)
- Bank of Montreal Can grew its position in Insmed Incorporated (NASDAQ:INSM) by 25.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,195 shares of the biopharmaceutical company’s stock after purchasing an additional 5,700 shares during the period. Bank of Montreal Can’s holdings in Insmed were […]
- 03/17/2020
|
Cowen & Co. Keeps Their Buy Rating on Insmed (INSM)
- In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Insmed (INSM), with a price target of $56.00. The company's
- 03/17/2020
|
Cowen & Co. Keeps Their Buy Rating on Insmed (INSM)
- In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Insmed (INSM – Research
- 03/17/2020
|
BRIEF-Insmed Says It Suspends Revenue Guidance
|
Insmed suspends revenue guidance amid coronavirus outbreak uncertainty
- Citing the impact of COVID-19, Insmed (NASDAQ:INSM) has suspended its 2020 revenue guidance of $180M - 220M.On the positive side, it has filed a marketing application in Japan for Arikayce (amikacin l
- 03/16/2020
|
Insmed Provides Business Update
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided a general business update.
- 03/16/2020
|
Franklin Resources Inc. Has $16.76 Million Holdings in Insmed Incorporated (NASDAQ:INSM)
- Franklin Resources Inc. grew its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 6.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 701,800 shares of the biopharmaceutical company’s stock after buying an additional 39,700 shares during the period. Franklin Resources Inc. owned approximately 0.79% of […]
- 03/16/2020
|
Insmed (NASDAQ:INSM) Stock Price Down 9.8%
- Shares of Insmed Incorporated (NASDAQ:INSM) dropped 9.8% on Wednesday . The company traded as low as $21.05 and last traded at $21.25, approximately 1,269,628 shares changed hands during trading. A decline of 6% from the average daily volume of 1,346,660 shares. The stock had previously closed at $23.55. INSM has been the topic of a […]
- 03/13/2020
|
Insmed Incorporated to Post Q2 2020 Earnings of ($0.44) Per Share, SVB Leerink Forecasts (NASDAQ:INSM)
- Insmed Incorporated (NASDAQ:INSM) – Analysts at SVB Leerink lifted their Q2 2020 earnings estimates for Insmed in a research report issued to clients and investors on Monday, March 9th. SVB Leerink analyst J. Schwartz now expects that the biopharmaceutical company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.51). […]
- 03/13/2020
|
BidaskClub Downgrades Insmed (NASDAQ:INSM) to Sell
- Insmed (NASDAQ:INSM) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, BidAskClub reports. A number of other equities research analysts have also recently issued reports on the company. Zacks Investment Research upgraded Insmed from a “sell” rating […]
- 03/09/2020
|
Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages
- Insmed Incorporated (NASDAQ:INSM) has been given an average rating of “Buy” by the ten research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1 year price target […]
- 03/08/2020
|
Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Charles Schwab Investment Management Inc.
- Charles Schwab Investment Management Inc. increased its stake in Insmed Incorporated (NASDAQ:INSM) by 2.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 546,594 shares of the biopharmaceutical company’s stock after acquiring an additional 11,348 shares during the period. Charles Schwab Investment Management Inc. owned approximately […]
- 03/07/2020
|
Asymmetry Capital Management L.P. Sells 136,709 Shares of Insmed Incorporated (NASDAQ:INSM)
- Asymmetry Capital Management L.P. trimmed its stake in Insmed Incorporated (NASDAQ:INSM) by 54.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 113,875 shares of the biopharmaceutical company’s stock after selling 136,709 shares during the quarter. Insmed makes up 4.9% of Asymmetry Capital Management L.P.’s […]
- 03/05/2020
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to three new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- 03/05/2020
|
BRIEF-Insmed Announces Publication Discussing Clinical Management Of Common Respiratory Events Associated With Arikayce
|
Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease
- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced publication of results from a survey of patients with refractory Mycobacterium avium complex (MAC) lung disease on the clinical management of respiratory adverse events (AEs) associated with ARIKAYCE® (amikacin liposome inhalation suspension) treatment. Results of the patient-directed study, conducted at Emory University in Atlanta, and Louisiana State University Health Science Center Clinics in New Orleans, were published in the peer-reviewed journal Open Forum Infectious Disease. The paper provides potential practical solutions to address the most common AEs that can accompany the use of ARIKAYCE in the treatment of refractory MAC lung disease.
- 03/04/2020
|
Edited Transcript of INSM earnings conference call or presentation 25-Feb-20 1:30pm GMT
- Q4 2019 Insmed Inc Earnings Call
- 03/02/2020
|
Los Angeles Capital Management & Equity Research Inc. Has $601,000 Stake in Insmed Incorporated (NASDAQ:INSM)
- Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Insmed Incorporated (NASDAQ:INSM) by 16.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,183 shares of the biopharmaceutical company’s stock after buying an additional 3,645 shares […]
- 02/28/2020
|
Insmed (NASDAQ:INSM) Shares Gap Down on Disappointing Earnings
- Insmed Incorporated (NASDAQ:INSM) gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $24.69, but opened at $26.34. Insmed shares last traded at $25.88, with a volume of 76,798 shares changing hands. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing […]
- 02/28/2020
|
Insmed Incorporated Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
- There's been a notable change in appetite for Insmed Incorporated (NASDAQ:INSM) shares in the week since its annual...
- 02/27/2020
|
Insmed Incorporated Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
- It's been a mediocre week for Insmed Incorporated (NASDAQ:INSM) shareholders, with the stock dropping 14% to US$26.32...
- 02/27/2020
|
Insmed (NASDAQ:INSM) Lifted to "Buy" at ValuEngine
- Insmed (NASDAQ:INSM) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports. INSM has been the topic of a number of other research reports. JMP Securities restated a “buy” rating and issued a $40.00 price target on shares of Insmed […]
- 02/27/2020
|
Galapagos Ratings Downgrade, And Other News: The Good, Bad And Ugly Of Biopharma
- Galapagos was down on a ratings downgrade. Insmed misses Q4 EPS. Perrigo gets an approval.
- 02/26/2020
|
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...
- 02/26/2020
|
Insmed to Present at the Cowen and Company 40th Annual Health Care Conference
- BRIDGEWATER, N.J., Feb. 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will…
- 02/26/2020
|
H.C. Wainwright Reaffirms Their Buy Rating on Insmed (INSM)
- H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed (INSM) today and set a price target of $52.00. The company's shares closed last
- 02/26/2020
|
Insmed (INSM) Q4 2019 Earnings Call Transcript
- INSM earnings call for the period ending December 31, 2019.
- 02/26/2020
|
Insmed, Incorporated (INSM) CEO Will Lewis on Q4 2019 Results - Earnings Call Transcript
- Insmed Incorporated (NASDAQ:INSM) Q4 2019 Earnings Conference Call February 25, 2020 8:30 AM ET Company Participants Eleanor Barisser - Investor Relations Will
- 02/25/2020
|
Insmed (INSM) Gets a Buy Rating from Cowen & Co.
- Cowen & Co. analyst Ritu Baral maintained a Buy rating on Insmed (INSM) today and set a price target of $56.00. The company's shares closed last
- 02/25/2020
|
Insmed (INSM) Gets a Buy Rating from Cowen & Co.
- Cowen & Co. analyst Ritu Baral maintained a Buy rating on Insmed (INSM – Research Report) today and set a
- 02/25/2020
|
BRIEF-Insmed Sees Full-Year 2020 Arikayce Revenue Of $180 Million To $220 Million
|
BRIEF-Insmed Reports Q4 Gaap Loss Per Share of $0.59
|
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 02/25/2020
|
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
- Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 02/25/2020
|
Insmed down 13% premarket on Q4 results
- Insmed (INSM) Q4 results:Revenues: $45.7M (+366.3%).Net loss: ($53M) (+42.1%); loss/share: ($0.59) (+50.4%); Quick Assets: $487.4M (-1.6%).2020 Guidance: ARIKAYCE revenue: $180M - 220M vs. $225.79M S&
- 02/25/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
- 02/25/2020
|
Insmed: 4Q Earnings Snapshot
- BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Tuesday reported a loss of $53 million in its fourth quarter.
On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 59 cents.
The results fell short of Wall Street expecta
- 02/25/2020
|
Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- BRIDGEWATER, N.J., Feb. 25, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,…
- 02/25/2020
|
Insmed, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Insmed, Inc. (NASDAQ:INSM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 25, 2020 at 8:30 AM ...
- 02/25/2020
|
Insmed Incorporated (NASDAQ:INSM) Shares Bought by Fmr LLC
- Fmr LLC boosted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 5.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,401,528 shares of the biopharmaceutical company’s stock after buying an additional 659,239 shares during the quarter. Fmr LLC owned approximately 15.00% of Insmed […]
- 02/25/2020
|
Insmed (INSM) to Release Quarterly Earnings on Tuesday
- Insmed (NASDAQ:INSM) will be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect Insmed to post earnings of ($0.59) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. Shares of NASDAQ:INSM opened at $31.25 on Friday. The […]
- 02/23/2020
|
FY2019 EPS Estimates for Insmed Incorporated (NASDAQ:INSM) Increased by Analyst
- Insmed Incorporated (NASDAQ:INSM) – Investment analysts at Svb Leerink boosted their FY2019 earnings estimates for shares of Insmed in a research note issued to investors on Tuesday, February 18th. Svb Leerink analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings per share of ($2.94) for the year, up from their previous forecast […]
- 02/23/2020
|
Insmed (NASDAQ:INSM) Raised to "Hold" at Zacks Investment Research
- Zacks Investment Research upgraded shares of Insmed (NASDAQ:INSM) from a sell rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients […]
- 02/22/2020
|
Is There An Opportunity With Insmed Incorporated's (NASDAQ:INSM) 49% Undervaluation?
- Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Insmed Incorporated...
- 02/20/2020
|
An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It’s 49% Undervalued
- Today we will run through one way of estimating the intrinsic value of Insmed Incorporated (NASDAQ:INSM) by taking the...
- 02/20/2020
|
Insmed to Present at the 9th Annual SVB Leerink Global Healthcare Conference
- BRIDGEWATER, N.J., Feb. 19, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will…
- 02/19/2020
|
Short Interest in Insmed Incorporated (NASDAQ:INSM) Drops By 8.6%
- Insmed Incorporated (NASDAQ:INSM) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 12,940,000 shares, a drop of 8.6% from the January 15th total of 14,150,000 shares. Based on an average trading volume of 946,400 shares, the days-to-cover ratio is presently 13.7 days. Currently, […]
- 02/17/2020
|
Insmed (INSM) Receives a Buy from Credit Suisse
- In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on Insmed (INSM), with a price target of $49.00. The company's
- 02/13/2020
|
Insmed (INSM) Receives a Buy from Credit Suisse
- In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on Insmed (INSM – Research Report),
- 02/13/2020
|
ArTara Therapeutics announces Blaine Davis as CFO TARA;INSM
- ArTara Therapeutics announces Blaine Davis as CFO TARA INSM
- 02/11/2020
|
Insmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020
- BRIDGEWATER, N.J., Feb. 10, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and year-end financial results on…
- 02/10/2020
|
Insmed (NASDAQ:INSM) Raised to "Hold" at BidaskClub
- BidaskClub upgraded shares of Insmed (NASDAQ:INSM) from a sell rating to a hold rating in a research note released on Wednesday, BidAskClub reports. Several other equities analysts have also recently issued reports on the company. Cowen restated a buy rating and issued a $56.00 price target on shares of Insmed in a research report on […]
- 02/08/2020
|
Bio Roundup: POTUS on Prices, a16z's Fund, Aimmune's Approval & More
- The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics:
- 02/07/2020
|
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- 02/07/2020
|
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
- 02/06/2020
|
HC Wainwright Reiterates "Buy" Rating for Insmed (NASDAQ:INSM)
- Insmed (NASDAQ:INSM)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, TipRanks reports. They currently have a $52.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 53.03% from the company’s previous close. Several other […]
- 02/06/2020
|
